Study S002380

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

ClinicalTrials.gov record

Registration

Registration: NCT06858839
Acronym: MARITIME-1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 3853
Start: 2025-03-12
Primary completion: 2027-01-21
Lead sponsor: Amgen
Conditions: Obesity
Interventions: DRUG:Maridebart Cafraglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: EUDRACT_NUMBER:2024-515524-36

Registered primary outcomes

Percent Change From Baseline in Body Weight at Week 72 [Baseline and Week 72]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.